About Avanir Pharmaceuticals (NASDAQ:AVNR)
AVANIR Pharmaceuticals, Inc. (AVANIR) is a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of central nervous system disorders. The Company focuses on products for the central nervous system. It also has a number of partnered programs in other therapeutic areas. Its docosanol 10% cream, sold in the United States and Canada as Abreva by its marketing partner GlaxoSmithKline Consumer Healthcare, is the only over-the-counter treatment for cold sores that has been approved by the United Sates Food and Drug Administration (FDA). In October 2010, FDA approved NUEDEXTA, is a combination of dextromethorphan/quinidine, for the treatment of pseudobulbar affect (PBA).
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
EPS (Most Recent Fiscal Year)N/A
Return on EquityN/A
Return on AssetsN/A
Avanir Pharmaceuticals (NASDAQ:AVNR) Frequently Asked Questions
What is Avanir Pharmaceuticals' stock symbol?
Avanir Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVNR."
Who are some of Avanir Pharmaceuticals' key competitors?
Some companies that are related to Avanir Pharmaceuticals include Apple (AAPL), Alphabet (GOOGL), Alphabet (GOOG), Amazon.com (AMZN), Microsoft (MSFT), Facebook (FB), Intel (INTC), Cisco Systems (CSCO), Comcast (CMCSA), PepsiCo (PEP), Netflix (NFLX), Nvidia (NVDA), Amgen (AMGN), Adobe Systems (ADBE), Booking (BKNG), Texas Instruments (TXN), Broadcom (AVGO) and Gilead Sciences (GILD).
Has Avanir Pharmaceuticals been receiving favorable news coverage?
Media headlines about AVNR stock have been trending somewhat positive this week, Accern reports. The research firm ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Avanir Pharmaceuticals earned a coverage optimism score of 0.14 on Accern's scale. They also gave media headlines about the healthcare company an impact score of 46.13 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
How do I buy shares of Avanir Pharmaceuticals?
Shares of AVNR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact Avanir Pharmaceuticals?
Avanir Pharmaceuticals' mailing address is 20 Enterprise Ste 200, ALISO VIEJO, CA 92656-7104, United States. The healthcare company can be reached via phone at +1-949-3896700.
MarketBeat Community Rating for Avanir Pharmaceuticals (AVNR)MarketBeat's community ratings are surveys of what our community members think about Avanir Pharmaceuticals and other stocks. Vote "Outperform" if you believe AVNR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVNR will underperform the S&P 500 over the long term. You may vote once every thirty days.
Avanir Pharmaceuticals (NASDAQ:AVNR) Analyst Ratings History
(Data available from 4/23/2016 forward)
|Date||Brokerage||Action||Rating||Price Target||Impact on Share Price||Details|
Avanir Pharmaceuticals (NASDAQ:AVNR) Earnings History and Estimates Chart
Avanir Pharmaceuticals (NASDAQ AVNR) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|12/10/2014||Q4 2014||($0.05)||($0.08)||$32.63 million||$32.71 million||View||N/A|
|8/5/2014||Q314||($0.08)||($0.08)||$29.46 million||$28.60 million||View||Listen|
|5/6/2014||Q214||($0.08)||($0.08)||$28.21 million||$26.95 million||View||Listen|
|2/5/2014||Q114||($0.08)||($0.07)||$24.84 million||$26.70 million||View||Listen|
|12/10/2013||Q4||($0.07)||($0.24)||$21.86 million||$21.70 million||View||Listen|
|8/6/2013||Q3 2013||($0.11)||($0.08)||$19.53 million||$19.80 million||View||Listen|
|5/8/2013||Q2 2013||($0.09)||($0.12)||$17.40 million||$17.40 million||View||Listen|
|2/7/2013||Q1 2013||($0.09)||($0.09)||$7.20 million||$16.50 million||View||Listen|
Avanir Pharmaceuticals (NASDAQ:AVNR) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Avanir Pharmaceuticals (NASDAQ AVNR) Insider Trading and Institutional Ownership History
Avanir Pharmaceuticals (NASDAQ AVNR) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|12/18/2014||Christine Ocampo||VP||Sell||35,780||$16.94||$606,113.20|| |
|12/18/2014||Joao Md Siffert||SVP||Sell||15,505||$16.93||$262,499.65|| |
|12/17/2014||Keith Katkin||CEO||Sell||277,680||$16.95||$4,706,676.00|| |
|11/28/2014||Rohan Palekar||SVP||Sell||15,000||$15.00||$225,000.00|| |
|10/24/2014||Christine Ocampo||VP||Sell||2,080||$11.81||$24,564.80|| |
|10/24/2014||Joao Md Siffert||SVP||Sell||8,426||$11.80||$99,426.80|| |
|10/24/2014||Keith Katkin||CEO||Sell||27,567||$11.76||$324,187.92|| |
|9/15/2014||Christine Ocampo||VP||Sell||55,000||$9.45||$519,750.00|| |
|9/15/2014||Rohan Palekar||SVP||Sell||25,000||$11.50||$287,500.00|| |
|8/1/2014||Keith Katkin||CEO||Sell||9,670||$5.26||$50,864.20|| |
|5/16/2014||Christine Ocampo||VP||Sell||37,496||$5.05||$189,354.80||81,981|| |
|12/17/2013||Rohan Palekar||SVP||Buy||10,000||$2.80||$28,000.00||143,000|| |
|11/4/2013||Rohan Palekar||SVP||Buy||10,000||$4.19||$41,900.00|| |
|9/18/2013||Joao Md Siffert||SVP||Sell||21,094||$4.22||$89,016.68||116,200|| |
|8/2/2013||Keith Katkin||CEO||Sell||15,500||$4.84||$75,020.00|| |
|5/15/2013||Christine Ocampo||VP||Sell||77,700||$3.29||$255,633.00|| |
|5/15/2013||Keith Katkin||CEO||Sell||250,438||$3.26||$816,427.88|| |
|12/13/2012||Rohan Palekar||SVP||Buy||10,000||$2.46||$24,600.00|| |
|12/3/2012||Christine Ocampo||VP||Sell||2,845||$2.55||$7,254.75|| |
|12/3/2012||Keith Katkin||CEO||Sell||18,250||$2.55||$46,537.50|| |
Avanir Pharmaceuticals (NASDAQ AVNR) News Headlines
|Reviewing Teva Pharmaceutical Industries (TEVA) & Avanir Pharmaceuticals (AVNR)|
www.americanbankingnews.com - March 17 at 7:08 PM
|Analyzing Theravance Biopharma (TBPH) & Avanir Pharmaceuticals (AVNR)|
www.americanbankingnews.com - October 16 at 8:30 PM
|Avanir Pharmaceuticals Appoints Richard Malamut, MD, as Senior Vice President, Research & Development, and Chief Medical Officer|
finance.yahoo.com - October 5 at 2:14 PM
|Report: KC-area docs who were paid the most by drug, device companies|
finance.yahoo.com - July 5 at 4:51 PM
|Avanir Pharma (AVNR) Launches ONZETRA Xsail in the US - StreetInsider.com|
www.streetinsider.com - May 16 at 1:45 PM
|MC10, Inc. Appoints Eric K. Brandt to its Board of Directors - Business Wire (press release)|
www.businesswire.com - April 1 at 9:49 PM
|Avanir Pharma (AVNR) Reports FDA Approval of ONZETRA to Treat Migraine - StreetInsider.com|
www.streetinsider.com - January 29 at 10:10 AM
|Acquisition of Avanir Pharmaceuticals, Inc. (AVNR) by Otsuka Pharmaceutical Co., Ltd. May Not Be in Shareholders' Best Interests|
www.prnewswire.com - January 23 at 9:36 AM
|Avanir Pharma Names Rohan Palekar As President And CEO, Succeeding Katkin|
www.nasdaq.com - January 21 at 4:54 PM
|Avanir Pharma Names Rohan Palekar As President And CEO, Succeeding Katkin - RTT News|
www.rttnews.com - January 20 at 9:43 AM
|Avanir Pharmaceuticals To Be Acquired By Otsuka Pharmaceutical For $3.5 Billion|
www.prnewswire.com - January 16 at 6:06 PM
|Japanese firm Otsuka to buy Avanir Pharmaceuticals for $3.5 billion|
www.latimes.com - December 2 at 8:39 PM
Avanir Pharmaceuticals (NASDAQ:AVNR) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Avanir Pharmaceuticals (NASDAQ:AVNR) Income Statement, Balance Sheet and Cash Flow Statement
Avanir Pharmaceuticals (NASDAQ AVNR) Stock Chart for Monday, April, 23, 2018